Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities

Abstract

Excess iron is tightly associated with tumorigenesis in multiple human cancer types through a variety of mechanisms including catalyzing the formation of mutagenic hydroxyl radicals, regulating DNA replication, repair and cell cycle progression, affecting signal transduction in cancer cells, and acting as an essential nutrient for proliferating tumor cells. Thus, multiple therapeutic strategies based on iron deprivation have been developed in cancer therapy. During the past few years, our understanding of genetic association and molecular mechanisms between iron and tumorigenesis has expanded enormously. In this review, we briefly summarize iron homeostasis in mammals, and discuss recent progresses in understanding the aberrant iron metabolism in numerous cancer types, with a focus on studies revealing altered signal transduction in cancer cells.

Keywords

Iron tumorigenesis / p53 / Wnt / DNA repair / cell cycle

References

[1] Chaston TB, Richardson DR (2003) Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol73: 200-210

[2] Chen G, Fillebeen C, Wang J, Pantopoulos K (2007) Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts. Carcinogenesis28: 785-791

[3] Chen Y, Zhang Z, Yang K, Du J, Xu Y, Liu S (2014) Myeloid zincfinger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene

[4] Cheng Z, Dai LL, Song YN, Kang Y, Si JM, Xia J, Liu YF (2014) Regulatory effect of iron regulatory protein-2 on iron metabolism in lung cancer. Genet Mol Res13: 5514-5522

[5] Cho H, Kim JH (2009) Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. J Histochem Cytochem57: 513-521

[6] Choi AM, Alam J (1996) Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidantinduced lung injury. Am J Respir Cell Mol Biol15: 9-19

[7] Crepin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA (2010) Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res70: 5497-5506

[8] Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta1820: 291-317

[9] Dayani PN, Bishop MC, Black K, Zeltzer PM (2004) Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol67: 367-377

[10] Denic S, Agarwal MM (2007) Nutritional iron deficiency: an evolutionary perspective. Nutrition23: 603-614

[11] Dongiovanni P, Fracanzani AL, Cairo G, Megazzini CP, Gatti S, Rametta R, Fargion S, Valenti L (2010) Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol176: 1006-1017

[12] Duarte DC, Nicolau A, Teixeira JA, Rodrigues LR (2011) The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci94: 66-76

[13] Dunn LL, Suryo Rahmanto Y, Richardson DR (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol17: 93-100

[14] Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J (2009) Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood114: 3064-3073

[15] Emanuele D, Tuason I, Edwards QT (2014) HFE-associated hereditary hemochromatosis: overview of genetics and clinical implications for nurse practitioners in primary care settings. J Am Assoc Nurse Pract26: 113-122

[16] Enyedy EA, Primik MF, Kowol CR, Arion VB, Kiss T, Keppler BK (2011) Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study. Dalton Trans40: 5895-5905

[17] Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA (2005) The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res11: 5390-5395

[18] Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol16: 4604-4613

[19] Fu D, Richardson DR (2007) Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood110: 752-761

[20] Gkouvatsos K, Papanikolaou G, Pantopoulos K (2012) Regulation of iron transport and the role of transferrin. Biochim Biophys Acta1820: 188-202

[21] Hamalainen P, Saltevo J, Kautiainen H, Mantyselka P, Vanhala M (2012) Erythropoietin, ferritin, haptoglobin, hemoglobin and transferrin receptor in metabolic syndrome: a case control study. Cardiovasc Diabetol11: 116

[22] Hewitson KS, McNeill LA, Elkins JM, Schofield CJ (2003) The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans31: 510-515

[23] Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, D’Alo F, Larocca LM, Raymakers RA, Swinkels DW (2010) Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol28: 2538-2543

[24] Hong CC, Ambrosone CB, Ahn J, Choi JY, McCullough ML, Stevens VL, Rodriguez C, Thun MJ, Calle EE (2007) Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomark Prev16: 1784-1794

[25] Hou Y, Zhang S, Wang L, Li J, Qu G, He J, Rong H, Ji H, Liu S (2012) Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Gene511: 398-403

[26] Iwasaki K, Ray PD, Huang BW, Sakamoto K, Kobayashi T, Tsuji Y (2013) Role of AMP-activated protein kinase in ferritin H gene expression by resveratrol in human T cells. Biochemistry52: 5075-5083

[27] Jakszyn PG, Allen NE, Lujan-Barroso L, Gonzalez CA, Key TJ, Fonseca-Nunes A, Tjonneland A, Fons-Johnsen N, Overvad K, Teucher B (2012) Nitrosamines and heme iron and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev21: 547-551

[28] Jiang XP, Elliott RL, Head JF (2010) Manipulation of iron transporter genes results in the suppression of human and mouse mammary adenocarcinomas. Anticancer Res30: 759-765

[29] Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA (2013) Inhibition of beta2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One8: e68366

[30] Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T (2012) Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol33: 1695-1700

[31] Kaplan CD, Kaplan J (2009) Iron acquisition and transcriptional regulation. Chem Rev109: 4536-4552

[32] Keith B, Johnson RS, Simon MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer12: 9-22

[33] Koc M, Taysi S, Sezen O, Bakan N (2003) Levels of some acutephase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull26: 1494-1497

[34] Koreth J, Antin JH (2010) Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica95: 364-366

[35] Kowdley KV (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology127: S79-86

[36] Kukulj S, Jaganjac M, Boranic M, Krizanac S, Santic Z, Poljak-Blazi M (2010) Altered iron metabolism, inflammation, transferrin receptors, and ferritin expression in non-small-cell lung cancer. Med Oncol27: 268-277

[37] Kumar D, Viberg J, Nilsson AK, Chabes A (2010) Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids Res38: 3975-3983

[38] Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, Choi AM (1997) Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem272: 5375-5381

[39] Lee SH, Pyo CW, Hahm DH, Kim J, Choi SY (2009) Iron-saturated lactoferrin stimulates cell cycle progression through PI3K/Akt pathway. Mol Cells28: 37-42

[40] Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF (2009) Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res69: 8579-8584

[41] Leng X, Wu Y, Arlinghaus RB (2011) Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol226: 309-314

[42] Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi B, Pintilie M, To C, Panchal D, Tsao MS (2012) Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One7: e46677

[43] Lill R, Hoffmann B, Molik S, Pierik AJ, Rietzschel N, Stehling O, Uzarska MA, Webert H, Wilbrecht C, Muhlenhoff U (2012) The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta1823: 1491-1508

[44] Lin X, Yang H, Zhou L, Guo Z (2011) Nrf2-dependent induction of NQO1 in mouse aortic endothelial cells overexpressing catalase. Free Radic Biol Med51: 97-106

[45] Lok CN, Ponka P (1999) Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem274: 24147-24152

[46] Lovejoy DB, Richardson DR (2003) Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr Med Chem10: 1035-1049

[47] MacDonald BT, Tamai K, He X (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell17: 9-26

[48] MacKenzie EL, Iwasaki K, Tsuji Y (2008) Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal10: 997-1030

[49] Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S (2010) In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood116: 3635-3644

[50] Mannelqvist M, Stefansson IM, Wik E, Kusonmano K, Raeder MB, Oyan AM, Kalland KH, Moses MA, Salvesen HB, Akslen LA (2012) Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer12: 169

[51] Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature454: 436-444

[52] Martin JH, Alalami O, Yaqoob F (2000) Differential effects of retinoids on nitric oxide production by promonocytic U937 cells and ZR-75-1 human breast cancer cells. Oncol Rep7: 219-223

[53] Miller JL (2013) Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med3: a011866

[54] Miyabe I, Kunkel TA, Carr AM (2011) The major roles of DNA polymerases epsilon and delta at the eukaryotic replication fork are evolutionarily conserved. PLoS Genet7: e1002407

[55] Molina-Montes E, Wark PA, Sanchez MJ, Norat T, Jakszyn P, LujanBarroso L, Michaud DS, Crowe F, Allen N, Khaw KT (2012) Dietary intake of iron, heme-iron and magnesium and pancreatic cancer risk in the European prospective investigation into cancer and nutrition cohort. Int J Cancer131: E1134-1147

[56] Moser JC, Rawal M, Wagner BA, Du J, Cullen JJ, Buettner GR (2013) Pharmacological ascorbate and ionizing radiation (IR) increase labile iron in pancreatic cancer. Redox Biol2: 22-27

[57] Muckenthaler MU, Galy B, Hentze MW (2008) Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr28: 197-213

[58] Mukhopadhyay CK, Mazumder B, Fox PL (2000) Role of hypoxiainducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem275: 21048-21054

[59] Munoz M, Gomez-Ramirez S, Martin-Montanez E, Auerbach M (2014) Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol20: 1972-1985

[60] Oh WK (2002) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer1: 81 -89

[61] Ornstein DL, Zacharski LR (2007) Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer58: 115-126

[62] Orrenius S, Nicotera P, Zhivotovsky B (2011) Cell death mechanisms and their implications in toxicology. Toxicol Sci119: 3-19

[63] Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, Gertig DM, Anderson GJ, Southey MC, Olynyk JK (2010) HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology51: 1311 -1318

[64] Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L (2012) Mechanisms of mammalian iron homeostasis. Biochemistry 51: 5705-5724

[65] Park KS, Kim H, Kim NG, Cho SY, Choi KH, Seong JK, Paik YK (2002) Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology35: 1459-1466

[66] Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, Johnson RS (2007) Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest117: 1926-1932

[67] Preston BD, Albertson TM, Herr AJ (2010) DNA replication fidelity and cancer. Semin Cancer Biol20: 281 -293

[68] Pusatcioglu CK, Nemeth E, Fantuzzi G, Llor X, Freels S, TussingHumphreys L, Cabay RJ, Linzmeier R, Ng D, Clark J (2014) Systemic and tumor level iron regulation in men with colorectal cancer: a case control study. Nutr Metab (Lond)11: 21

[69] Radulescu S, Brookes MJ, Salgueiro P, Ridgway RA, McGhee E, Anderson K, Ford SJ, Stones DH, Iqbal TH, Tselepis C (2012) Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo. Cell Rep2: 270-282

[70] Richardson DR, Kalinowski DS, Richardson V, Sharpe PC, Lovejoy DB, Islam M, Bernhardt PV (2009) 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity. J Med Chem52: 1459-1470

[71] Romero A, Ramos E, de Los Rios C, Egea J, Del Pino J, Reiter RJ (2014) A review of metal-catalyzed molecular damage: protection by melatonin. J Pineal Res56: 343-370

[72] Rossi E (2005) Hepcidin – the iron regulatory hormone. Clin Biochem Rev26: 47-49

[73] Rouault TA (2003) How mammals acquire and distribute iron needed for oxygen-based metabolism. PLoS Biol1: E79

[74] Rouault TA (2006) The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol2: 406-414

[75] Sakurai K, Sohda T, Ueda S, Tanaka T, Hirano G, Yokoyama K, Mori hara D, Aanan A, Takeyama Y, Irie M (2014) Immunohistochemi cal demonstration of transferri n receptor 1 and 2 in human hepatocellular carcinoma tissue. Hepatogastroenterology61: 426-430

[76] Sarkar A, Sil PC (2014) Iron oxide nanoparticles mediated cytotoxicity via PI3K/AKT pathway: role of quercetin. Food Chem Toxicol71: 106-115

[77] Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X (2014) Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. Cell Rep7: 180-193

[78] Shiiba M, Saito K, Fushimi K, Ishigami T, Shinozuka K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A, Sakamoto Y (2013) Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. Int J Oncol42: 1197-1204

[79] Shpyleva SI, Tryndyak VP, Kovalchuk O, Starlard-Davenport A, Chekhun VF, Beland FA, Pogribny IP (2011) Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat126: 63-71

[80] Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett267: 204-215

[81] Siriwardana G, Seligman PA (2013) Two cell cycle blocks caused by iron chelation of neuroblastoma cells: separating cell cycle events associated with each block. Physiol Rep1: e00176

[82] Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M (2011) Wnt inhibitor screen reveals iron dependence of beta-catenin signaling in cancers. Cancer Res71: 7628-7639

[83] Stocker R (1990) Induction of haem oxygenase as a defence against oxidative stress. Free Radic Res Commun9: 101 -112

[84] Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G (1999) Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem274: 24142-24146

[85] Tammariello AE, Milner JA (2010) Mouse models for unraveling the importance of diet in colon cancer prevention. J Nutr Biochem21: 77-88

[86] Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM (2009) Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood)234: 693-702

[87] Tenga MJ, Lazar IM (2014) Proteomic study reveals a functional network of cancer markers in the G1-Stage of the breast cancer cell cycle. BMC Cancer14: 710

[88] Thomas C, Mackey MM, Diaz AA, Cox DP (2009) Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. Redox Rep14: 102-108

[89] Torti SV, Torti FM (2013) Iron and cancer: more ore to be mined. Nat Rev Cancer13: 342-355

[90] Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal10: 1343-1374

[91] Tsui KH, Chung LC, Wang SW, Feng TH, Chang PL, Juang HH (2013) Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol51: 131 -141

[92] Vakkala M, Paakko P, Soini Y (2000) eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. Int J Oncol17: 667-671

[93] Valerio LG (2007) Mammalian iron metabolism. Toxicol Mech. Methods17: 497-517

[94] Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffman RM (1990) The distinction of small cell and nonsmall cell lung cancer by growth in native-state histoculture. Cancer Res50: 6095-6099

[95] von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA (2012) Wnt signaling in myogenesis. Trends Cell Biol22: 602-609

[96] Wang J, Pantopoulos K (2002) Conditional derepression of ferritin synthesis in cells expressing a constitutive IRP1 mutant. Mol Cell Biol22: 4638-4651

[97] Wang J, Li Q, Ou Y, Han Z, Li K, Wang P, Zhou S (2011) Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res34: 987-995

[98] Wang N, Wei H, Yin D, Lu Y, Zhang Y, Jiang D, Jiang Y, Zhang S (2014) Cyclin D1b overexpression inhibits cell proliferation and induces cell apoptosis in cervical cancer cells in vitro and in vivo. Int J Clin Exp Pathol7: 4016-4023

[99] Ward PP, Mendoza-Meneses M, Cunningham GA, Conneely OM (2003) Iron status in mice carrying a targeted disruption of lactoferrin. Mol Cell Biol23: 178-185

[100] Wu Y, Brosh RM Jr (2012) DNA helicase and helicase-nuclease enzymes with a conserved iron-sulfur cluster. Nucleic Acids Res40: 4247-4260

[101] Wyllie S, Liehr JG (1997) Release of iron from ferritin storage by redox cycling of stilbene and steroid estrogen metabolites: a mechanism of induction of free radical damage by estrogen. Arch Biochem Biophys346: 180-186

[102] Xiong W, Wang L, Yu F (2014) Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol31: 28

[103] Xue X, Shah YM (2013) Intestinal iron homeostasis and colon tumorigenesis. Nutrients5: 2333-2351

[104] Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ, Shah YM (2012) Hypoxiainducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res72: 2285-2293

[105] Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA (2009) Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A106: 3913-3918

[106] Yang J, McNeish B, Butterfield C, Moses MA (2013) Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J27: 45-50

[107] Yildirim A, Meral M, Kaynar H, Polat H, Ucar EY (2007) Relationship between serum levels of some acute-phase proteins and stage of disease and performance status in patients with lung cancer. Med Sci Monit13: CR195-200

[108] Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res12: 6876-6883

[109] Zhang C (2014) Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell5: 750-760

[110] Zhang F, Wang W, Tsuji Y, Torti SV, Torti FM (2008) Posttranscriptional modulation of iron homeostasis during p53-dependent growth arrest. J Biol Chem283: 33911-33918

[111] Zhang F, Tao Y, Zhang Z, Guo X, An P, Shen Y, Wu Q, Yu Y, Wang F (2012) Metalloreductase Steap3 coordinates the regulation of iron homeostasis and inflammatory responses. Haematologica97: 1826-1835

[112] Zhang C, Liu G, Huang M (2014) Ribonucleotide reductase metallocofactor: assembly, maintenance and inhibition. Front Biol (Beijing)9: 104-113

[113] Zhao N, Gao J, Enns CA, Knutson MD (2010) ZRT/IRT-like protein 14 (ZIP14) promotes the cellular assimilation of iron from transferrin. J Biol Chem285: 32141-32150

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.